{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \\>5.1, low disease activity: DAS28-CRP \\<3.2, and remission: DAS28-CRP \\<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and \\>1.2 improvement from baseline), moderate (absolute: \\>3.2 and ≤5.1 and \\>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \\>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \\* 100.","groups":[{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"OG000","title":"Combined 4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"OG001","title":"Combined 8 mg Baricitinib (LY3009104)"}],"paramType":"NUMBER","populationDescription":"All participants who received any amount of study drug in Part B.","reportingStatus":"POSTED","timeFrame":"Baseline up to 64 weeks","title":"Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}